The purpose of this study is to find out if providing patients with educational materials helps them to be better prepared for making a decision about participating in a research study to treat their cancer.
The purpose of this study is to find out if radiation therapy along with the addition of the drugs, cisplatin and gemcitabine, works in treating locally advanced squamous cell carcinoma of the vulva and to find out what side effects or surgical complications are caused by treatment with this combination.
The purpose of this study is to test whether the use of radiation therapy delivery technique called intensity-modulated radiation therapy (IMRT) can reduce the amount and severity of gastrointestinal side effects (such as diarrhea) that result from radiation, compared with standard radiation techniques. In this study patients will get either the IMRT or the standard radiation. Radiation treatment will be delivered daily (Monday through Friday) for 5-6 weeks. Patients may or may not receive weekly cisplatin chemotherapy along with radiation therapy; this will be decided by the treating physician. Following completion of the radiation treatment, patients will be followed for total of 10 years.
This is a Phase II study for women diagnosed with pelvic-only and or vaginal recurrence of endometrial cancer following complete hysterectomy and bilateral salpingo-oophorectomy at the time of initial diagnosis . Patients will be randomized to receive external pelvic radiation for approximately 5 weeks followed by brachytherapy OR external pelvic radiation for approximately 5 weeks plus weekly chemotherapy with cisplatin followed by brachytherapy. The study is designed as a screening study to estimate the benefit on progression-free survival of the addition of cisplatin to external pelvic irradiation, overall survival, side effects and evaluate factors at study entry and from original hysterectomy as potential prognostic factors.
This study is for women who have completed treatment (chemotherapy and other treatment) for state II, III, or IV ovarian, fallopian tube or primary peritoneal cancer (cancer having to do with the tissue that lines the inside of the abdomen and covers its organs) and are at risk for the cancer coming back.
This study is for female adult subjects with ovarian cancer. CA125 is a protein (compound made by the body) found in blood that is used to monitor treatments and disease progression in ovarian cancer patients. HE4 is also a protein that is used in the evaluation of ovarian cancer and disease monitoring. Both CA125 and HE4 are approved by the FDA to monitor the treatment of ovarian cancers. The purpose of this study is to investigate HE4 and CA125 expressions in different types of ovarian cancer and to evaluate the changes in HE4 and CA125 before and after treatment. A blood draw of approximately 5mL or 1 teaspoon will be taken from eligible subjects before surgery, before each course of chemotherapy and at the time of disease response assessment to evaluate HE4 and CA125 expression.
Multiple radiation treatments are frequently used to treat pain caused by cancer that has spread to the spine. Image-guided radiosurgery/stereotactic body radiation therapy (SBRT) is a treatment that uses highly focused x-rays to deliver a single high dose on a specific area of the body. Image-guided radiosurgery/SBRT uses special equipment to position the patient and guide the focused beams toward the area to be treated and away from normal tissue.
The purpose of this part of the study is to compare the effects, good and/or bad, of image-guided radiosurgery/SBRT to standard radiation therapy to find out which treatment provides the most rapid pain relief with the least side effects.
This study is for adult women who have advanced or recurrent endometrial (uterine) cancer. The purpose is to find out if the drug combination of paclitaxel, carboplatin and metformin works better than paclitaxel and carboplatin alone in treating uterine cancer.
The objectives of this trial are to find out whether adjuvant chemotherapy (using two other drugs) after chemo-radiation will increase the chances of survival and reduce the risk of tumor recurrence in the pelvis and other places. The risk and severity of side effects and quality of life during and after treatment will also be evaluated and compared. This trial will help the researchers understand the safety and effectiveness of this new treatment regimen for cervical cancer.